Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography.
Hypovascular pancreatic neuroendocrine tumors (hypo-PNETs) are often misdiagnosed as pancreatic ductal adenocarcinoma (PDAC). However, the treatment options and prognosis of PNETs and PDAC are substantially different. This retrospective study differentiated hypo-PNETs from PDAC using contrast-enhanc...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0211566 |
| _version_ | 1819016519039844352 |
|---|---|
| author | Shuai Ren Xiao Chen Zhonglan Wang Rui Zhao Jianhua Wang Wenjing Cui Zhongqiu Wang |
| author_facet | Shuai Ren Xiao Chen Zhonglan Wang Rui Zhao Jianhua Wang Wenjing Cui Zhongqiu Wang |
| author_sort | Shuai Ren |
| collection | DOAJ |
| description | Hypovascular pancreatic neuroendocrine tumors (hypo-PNETs) are often misdiagnosed as pancreatic ductal adenocarcinoma (PDAC). However, the treatment options and prognosis of PNETs and PDAC are substantially different. This retrospective study differentiated hypo-PNETs from PDAC using contrast-enhanced CT (CE-CT). Clinical data and CE-CT findings, including tumor location, size, boundary, pancreatic duct dilatation, local invasion or metastases, tumor contrast enhancement, and tumor-to-pancreas enhancement ratio, were compared between 39 PDACs and 18 hypo-PNETs. At CT imaging, hypo-PNETs showed a higher frequency of a well-defined margin and lower frequencies of pancreatic duct dilatation and local invasion or metastasis when compared with PDAC (p < 0.05 for all). The mean attenuation of hypo-PNETs at the arterial and portal venous phase was significantly higher than that of PDAC (p < 0.001, p = 0.003, respectively). Similar results were observed in tumor-to-pancreas enhancement ratio. Tumor attenuation and tumor-to-pancreas enhancement ratio at the arterial phase showed the largest area under the curve (AUC) of 0.888 and 0.812 with 83.3-88.9% of sensitivity and 61.6-77.0% of specificity. Pancreatic duct dilatation, local invasion or metastasis, and tumor attenuation at the portal venous phase also showed acceptable AUC (0.703-0.748). Thus CE-CT features, especially the enhancement degree at the arterial phases, may be useful for differentiating hypo-PNETs from PDAC using CE-CT. |
| first_indexed | 2024-12-21T02:48:55Z |
| format | Article |
| id | doaj.art-41fd5de758424e16bb3af48b86c1c8a0 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T02:48:55Z |
| publishDate | 2019-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-41fd5de758424e16bb3af48b86c1c8a02022-12-21T19:18:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01142e021156610.1371/journal.pone.0211566Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography.Shuai RenXiao ChenZhonglan WangRui ZhaoJianhua WangWenjing CuiZhongqiu WangHypovascular pancreatic neuroendocrine tumors (hypo-PNETs) are often misdiagnosed as pancreatic ductal adenocarcinoma (PDAC). However, the treatment options and prognosis of PNETs and PDAC are substantially different. This retrospective study differentiated hypo-PNETs from PDAC using contrast-enhanced CT (CE-CT). Clinical data and CE-CT findings, including tumor location, size, boundary, pancreatic duct dilatation, local invasion or metastases, tumor contrast enhancement, and tumor-to-pancreas enhancement ratio, were compared between 39 PDACs and 18 hypo-PNETs. At CT imaging, hypo-PNETs showed a higher frequency of a well-defined margin and lower frequencies of pancreatic duct dilatation and local invasion or metastasis when compared with PDAC (p < 0.05 for all). The mean attenuation of hypo-PNETs at the arterial and portal venous phase was significantly higher than that of PDAC (p < 0.001, p = 0.003, respectively). Similar results were observed in tumor-to-pancreas enhancement ratio. Tumor attenuation and tumor-to-pancreas enhancement ratio at the arterial phase showed the largest area under the curve (AUC) of 0.888 and 0.812 with 83.3-88.9% of sensitivity and 61.6-77.0% of specificity. Pancreatic duct dilatation, local invasion or metastasis, and tumor attenuation at the portal venous phase also showed acceptable AUC (0.703-0.748). Thus CE-CT features, especially the enhancement degree at the arterial phases, may be useful for differentiating hypo-PNETs from PDAC using CE-CT.https://doi.org/10.1371/journal.pone.0211566 |
| spellingShingle | Shuai Ren Xiao Chen Zhonglan Wang Rui Zhao Jianhua Wang Wenjing Cui Zhongqiu Wang Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. PLoS ONE |
| title | Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. |
| title_full | Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. |
| title_fullStr | Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. |
| title_full_unstemmed | Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. |
| title_short | Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. |
| title_sort | differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast enhanced computed tomography |
| url | https://doi.org/10.1371/journal.pone.0211566 |
| work_keys_str_mv | AT shuairen differentiationofhypovascularpancreaticneuroendocrinetumorsfrompancreaticductaladenocarcinomausingcontrastenhancedcomputedtomography AT xiaochen differentiationofhypovascularpancreaticneuroendocrinetumorsfrompancreaticductaladenocarcinomausingcontrastenhancedcomputedtomography AT zhonglanwang differentiationofhypovascularpancreaticneuroendocrinetumorsfrompancreaticductaladenocarcinomausingcontrastenhancedcomputedtomography AT ruizhao differentiationofhypovascularpancreaticneuroendocrinetumorsfrompancreaticductaladenocarcinomausingcontrastenhancedcomputedtomography AT jianhuawang differentiationofhypovascularpancreaticneuroendocrinetumorsfrompancreaticductaladenocarcinomausingcontrastenhancedcomputedtomography AT wenjingcui differentiationofhypovascularpancreaticneuroendocrinetumorsfrompancreaticductaladenocarcinomausingcontrastenhancedcomputedtomography AT zhongqiuwang differentiationofhypovascularpancreaticneuroendocrinetumorsfrompancreaticductaladenocarcinomausingcontrastenhancedcomputedtomography |